Comparative Pharmacology
Head-to-head clinical analysis: MEGESTROL ACETATE versus NORLUTIN.
Head-to-head clinical analysis: MEGESTROL ACETATE versus NORLUTIN.
MEGESTROL ACETATE vs NORLUTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic progestin with antineoplastic activity; suppresses pituitary gonadotropin secretion and exerts direct cytotoxic effects on endometrial cancer cells via binding to progesterone receptors. Also stimulates appetite through unclear mechanisms, possibly involving neuropeptide Y and inhibition of proinflammatory cytokines.
Synthetic progestin that binds to progesterone receptors, suppressing gonadotropin secretion and altering endometrial lining.
400 mg orally once daily or 800 mg orally once daily (suspension) for appetite stimulation; 40-320 mg orally daily in divided doses for endometrial cancer.
5 mg orally three times daily for endometriosis; 5 mg orally daily from day 5 to day 25 of menstrual cycle for amenorrhea.
None Documented
None Documented
Clinical Note
moderateMegestrol acetate + Digoxin
"Megestrol acetate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMegestrol acetate + Digitoxin
"Megestrol acetate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMegestrol acetate + Deslanoside
"Megestrol acetate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMegestrol acetate + Acetyldigitoxin
Terminal half-life: 13-105 hours (mean ~34 hours) in adults; prolonged in hepatic impairment.
Terminal elimination half-life: 5–14 hours (mean ~8 hours). Clinical context: short half-life necessitates daily dosing for contraceptive efficacy.
Renal: 50-79% as glucuronide conjugates; fecal: 8-30%; biliary: minor.
Mainly renal as glucuronide and sulfate conjugates; approximately 70% renal, 30% fecal/biliary.
Category D/X
Category C
Progestin
Progestin
"Megestrol acetate may decrease the cardiotoxic activities of Acetyldigitoxin."